The global optical preclinical imaging market size was valued at USD 640.40 Million in 2024, driven by rising technical advancements in optical imaging facilitating smooth drug development across the globe. The market is expected to grow at a CAGR of 5.00% during the forecast period of 2025-2034, with the values likely to rise from USD 1.04 billion by 2034.
Animals are often used as the initial model for testing and determining the effects of a drug. However, collecting the data sets can be difficult, owing to their different sizes and physical positions. To solve this problem, InVivo analytics has developed a fast cloud-based data analysis platform called InVIvoAX. Imaging software like Harmony® and Columbus™ are being used for high content imaging, data storage and analysis.
The optical preclinical imaging market growth can also be accredited to the advent of new imaging technologies. Researchers have introduced imaging mass cytometry to analyze the detection of proteins within tissue sections with the help of heavy metal tagged antibodies. In September 2023, Revvity Inc., unveiled an enhanced imaging portfolio in preclinical research which includes IVIS® Spectrum 2 and the IVIS SpectrumCT 2 imaging systems, crafted to elevate the sensitivity standards in in vivo optical imaging.
To facilitate fast-tracking and rapid evaluation of therapeutic candidates, Revvity's QuantumTM GX3 microCT structural imaging solution has been enabled with increased resolution and speed for both in vivo and ex vivo imaging. Such product launches will add significant growth the optical preclinical imaging market value.
Europe has been one of the leading regions in the market as it is home to several academic institutions, pioneering research and development in numerous healthcare domains. Asia Pacific is also expected to witness the fastest growth attributed to rising medical infrastructure development. In addition, major healthcare companies have been making hefty investments in the region to leverage the easy availability of both economical and intellectual resources.
This product will be delivered within 3-5 business days.
Optical Preclinical Imaging: Introduction
Preclinical imaging is an essential diagnostic and research tool used in drug development and discovery. Preclinical imaging includes micro-ultrasound, optical imaging, CT, PET, and MRIs, among others. Optical imaging is divided into bioluminescence and fluorescence. It is rapid, easy to perform, and is commonly used for molecular visualizations. It can prove to be highly effective for the pharmaceutical industry as it enables the prior analysis of drugs in pipeline, facilitating faster drug development.Global Optical Preclinical Imaging Market Analysis
The sudden outbreak of COVID-19 and increasing prevalence of chronic diseases has expediated drug and vaccine development. With the ongoing trend of machine learning and artificial intelligence, the healthcare industry is witnessing the convergence of new technologies into medical ecosystem. This is has led to significant optical preclinical imaging market demand.Animals are often used as the initial model for testing and determining the effects of a drug. However, collecting the data sets can be difficult, owing to their different sizes and physical positions. To solve this problem, InVivo analytics has developed a fast cloud-based data analysis platform called InVIvoAX. Imaging software like Harmony® and Columbus™ are being used for high content imaging, data storage and analysis.
The optical preclinical imaging market growth can also be accredited to the advent of new imaging technologies. Researchers have introduced imaging mass cytometry to analyze the detection of proteins within tissue sections with the help of heavy metal tagged antibodies. In September 2023, Revvity Inc., unveiled an enhanced imaging portfolio in preclinical research which includes IVIS® Spectrum 2 and the IVIS SpectrumCT 2 imaging systems, crafted to elevate the sensitivity standards in in vivo optical imaging.
To facilitate fast-tracking and rapid evaluation of therapeutic candidates, Revvity's QuantumTM GX3 microCT structural imaging solution has been enabled with increased resolution and speed for both in vivo and ex vivo imaging. Such product launches will add significant growth the optical preclinical imaging market value.
Global Optical Preclinical Imaging Market Segmentation
Optical Preclinical Imaging Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:Market Breakup by Modality
- Bioluminescence/Fluorescence Imaging Systems
- Standalone Fluorescence Imaging Systems
- Optical + X-Ray/ Optical + CT
Market Breakup by Reagent
- Bioluminescent Imaging Reagents
- Fluorescent Imaging Reagent
Market Breakup by Application
- Research and Development
- Drug Discovery
Market Breakup by End User
- Pharma and Biotech Companies
- Research Institutes
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Optical Preclinical Imaging Market Overview
The United States is expected to lead the optical preclinical imaging market share with the implementation of the Inflation Reduction Act of 2022. This act emphasizes the reduction of device and drug prices in the country. This indicates that the traditional research and development methods will take a backseat as the pharma companies keenly adopt machine learning and artificial intelligence technology driven platforms to accelerate drug development. The integration has already been initiated and it is fairly smooth, owing to the presence of a robust healthcare infrastructure.Europe has been one of the leading regions in the market as it is home to several academic institutions, pioneering research and development in numerous healthcare domains. Asia Pacific is also expected to witness the fastest growth attributed to rising medical infrastructure development. In addition, major healthcare companies have been making hefty investments in the region to leverage the easy availability of both economical and intellectual resources.
Global Optical Preclinical Imaging Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:- Stryker
- Smith+Nephew
- NuVasive Inc.
- Arthrex Inc.
- Orthofix US LLC
- Johnson & Johnson Services, Inc.
- Pega Medical Inc.
- WishBone Medical
- Zimmer Biomet
- Medtronic
- Auxein Medical
- Implanet SA
- Merete GmbH
- Mighty Oak Medical
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Global Optical Preclinical Imaging Market Overview
4 Global Optical Preclinical Imaging Market Landscape
5 Global Optical Preclinical Imaging Market Dynamics
6 Global Optical Preclinical Imaging Market Segmentation
7 North America Optical Preclinical Imaging Market
8 Europe Optical Preclinical Imaging Market
9 Asia Pacific Optical Preclinical Imaging Market
10 Latin America Optical Preclinical Imaging Market
11 Middle East and Africa Optical Preclinical Imaging Market
12 Patent Analysis
13 Grants Analysis
14 Funding & Investment Analysis
15 Partnership and Collaborations Analysis
16 Supplier Landscape
17 Global Optical Preclinical Imaging Market - Distribution Model (Additional Insight)
19 Company Competitiveness Analysis (Additional Insight)
20 Payment Methods (Additional Insight)
Companies Mentioned
- Stryker
- Smith+Nephew
- NuVasive Inc.
- Arthrex Inc.
- Financial Portfolio
- Orthofix US LLC
- Johnson & Johnson Services, Inc.
- Pega Medical Inc.
- WishBone Medical
- Zimmer Biomet
- Medtronic
- Auxein Medical
- Implanet SA
- Merete GmbH
- Mighty Oak Medical